These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 1568223)
41. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Yano T; Pinski J; Radulovic S; Schally AV Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868 [TBL] [Abstract][Full Text] [Related]
42. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin. Kadar T; Redding TW; Ben-David M; Schally AV Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378 [TBL] [Abstract][Full Text] [Related]
43. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420 [TBL] [Abstract][Full Text] [Related]
44. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV Prostate; 1994; 24(2):84-92. PubMed ID: 7508623 [TBL] [Abstract][Full Text] [Related]
45. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Sharoni Y; Bosin E; Miinster A; Levy J; Schally AV Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1648-51. PubMed ID: 2646641 [TBL] [Abstract][Full Text] [Related]
46. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat. Ayalon D; Farhi Y; Comaru-Schally AM; Schally AV; Eckstein N; Vagman I; Limor R Neuroendocrinology; 1993 Aug; 58(2):153-9. PubMed ID: 8264861 [TBL] [Abstract][Full Text] [Related]
47. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. Redding TW; Coy DH; Schally AV Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1273-6. PubMed ID: 6803239 [TBL] [Abstract][Full Text] [Related]
48. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Paz-Bouza JI; Redding TW; Schally AV Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296 [TBL] [Abstract][Full Text] [Related]
49. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. Halmos G; Schally AV; Kahan Z Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548 [TBL] [Abstract][Full Text] [Related]
50. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75). Pinski J; Schally AV; Yano T; Groot K; Srkalovic G; Serfozo P; Reissmann T; Bernd M; Deger W; Kutscher B Int J Pept Protein Res; 1995 May; 45(5):410-7. PubMed ID: 7591480 [TBL] [Abstract][Full Text] [Related]
51. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Fekete M; Redding TW; Comaru-Schally AM; Pontes JE; Connelly RW; Srkalovic G; Schally AV Prostate; 1989; 14(3):191-208. PubMed ID: 2471961 [TBL] [Abstract][Full Text] [Related]
52. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. Pinski J; Yano T; Miller G; Schally AV Prostate; 1992; 20(3):213-24. PubMed ID: 1533453 [TBL] [Abstract][Full Text] [Related]
53. Protective effects of analogs of luteinizing hormone-releasing hormone against x-radiation-induced testicular damage in rats. Schally AV; Paz-Bouza JI; Schlosser JV; Karashima T; Debeljuk L; Gandle B; Sampson M Proc Natl Acad Sci U S A; 1987 Feb; 84(3):851-5. PubMed ID: 2949328 [TBL] [Abstract][Full Text] [Related]
54. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone. Torres-Aleman I; Redding TW; Schally AV Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096 [TBL] [Abstract][Full Text] [Related]
55. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Schally AV; Redding TW; Comaru-Schally AM Prostate; 1983; 4(6):545-52. PubMed ID: 6226942 [TBL] [Abstract][Full Text] [Related]
56. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Srkalovic G; Szende B; Redding TW; Groot K; Schally AV Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866 [TBL] [Abstract][Full Text] [Related]
57. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma. Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV Prostate; 1989; 14(4):291-300. PubMed ID: 2526325 [TBL] [Abstract][Full Text] [Related]
58. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Szende B; Srkalovic G; Schally AV; Lapis K; Groot K Cancer; 1990 May; 65(10):2279-90. PubMed ID: 1971771 [TBL] [Abstract][Full Text] [Related]
59. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats. Karashima T; Zalatnai A; Schally AV Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2329-33. PubMed ID: 2965391 [TBL] [Abstract][Full Text] [Related]
60. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]